EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Peptide receptor radionuclide therapy (PRRT) in high grade neuroendocrine neoplasms: a systematic review and meta-analysis

Emilia Zampella, Leandra Piscopo, Roberta Green, Valeria Cantoni, Carmela Nappi, Valeria Gaudieri, Elisa Caiazzo, Mariano Scaglione, Alberto Cuocolo iD, Michele Klain

European Journal of Nuclear Medicine and Molecular Imaging · 2026-05 · 53 (6) · 3799-3808

DOI: 10.1007/s00259-025-07726-w ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 03.01.2026. Verfasst von Emilia Zampella und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Pansini 5, 80131, Naples, Italy. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Receptors, Peptide, Pancreatic Neoplasms, Stomach Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: We performed a systematic review and meta-analysis to investigate the efficacy of peptide receptor radionuclide therapy (PRRT) by using radiolabeled somatostatin analogues in high grade gastro-entero-pancreatic neoplasms (GEP-NEN). METHODS: All clinical studies published up to March 2025, including patients with grade 3 (G3) GEP-NEN treated with [177Lu] Lu-DOTA-TATE and/or [90Y] Y-SSA, were identified based on systematic searches in the PubMed and Embase databases. Eligible studies had to report at least one of the following outcomes: 1) response to therapy evaluated according to RECIST (version 1.1 as complete response, partial response, stable disease, progressive disease; 2) median progression free survival (PFS) with 95% confidence intervals (CI); 3) median overall survival (OS) with 95% CI. Objective response rate (ORR) and disease control rate (DCR) were considered as primary outcomes. RESULTS: The final analysis included 7 studies accounting for a total of 317 patients with G3 disease (ranging from 18 to 112). Six studies evaluated response to therapy according to RECIST in 288 patients, and in 4 of them patients were also stratified according to ki67 values. The pooled ORR and DCR were 34% (95% CI: 22-46) and 64% (95% CI: 52-76), respectively. The funnel plot indicated no publication bias among these studies. Five studies reported in 239 patients median PFS with 95% CI, with a pooled estimate of 13.88 (95% CI: 10.33-18.64) months. Three studies fully reported in 174 patients median OS with 95% CI, with a pooled estimate of 29.95 (95% CI: 19.80-45.30) months. CONCLUSIONS: In patients with G3 GEP-NEN, PRRT may provide substantial disease control and response rates, and it seems able to delay the progression of the disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsReceptors, PeptidePancreatic NeoplasmsStomach NeoplasmsHumansNeoplasm GradingTreatment OutcomeRadiopharmaceuticalsOctreotide

Stichwörter der Autor:innen

Neuroendocrine neoplasmPRRTSomatostatin analogues, Prognosis

Substanzen

Receptors, PeptideRadiopharmaceuticalsOctreotide

Autor:innen und Institutionen

  • Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Pansini 5, 80131, Naples, Italy.
  • Department of Radiology, University of Sassari, Sassari, Italy.
  • IRCCS Synlab SDN, Naples, Italy.
  • Nuclear Medicine Unit, University Hospital Federico II, Naples, Italy.
  • Department of Advanced Biomedical Sciences, University of Naples Federico II, Via Pansini 5, 80131, Naples, Italy. cuocolo@unina.it.
  • IRCCS Synlab SDN, Naples, Italy. cuocolo@unina.it.

ORCID-Profile: Alberto Cuocolo

Zitieren

APA

Zampella, E., Piscopo, L., Green, R., Cantoni, V., Nappi, C., Gaudieri, V., Caiazzo, E., Scaglione, M., Cuocolo, A., & Klain, M. (2026). Peptide receptor radionuclide therapy (PRRT) in high grade neuroendocrine neoplasms: a systematic review and meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 53(6), 3799-3808. https://doi.org/10.1007/s00259-025-07726-w

Vancouver

Zampella E, Piscopo L, Green R, Cantoni V, Nappi C, Gaudieri V, et al. Peptide receptor radionuclide therapy (PRRT) in high grade neuroendocrine neoplasms: a systematic review and meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(6):3799-3808. doi:10.1007/s00259-025-07726-w

BibTeX
@article{Zampella2026,
  author = {Zampella, Emilia and Piscopo, Leandra and Green, Roberta and Cantoni, Valeria and Nappi, Carmela and Gaudieri, Valeria and Caiazzo, Elisa and Scaglione, Mariano and Cuocolo, Alberto and Klain, Michele},
  title = {Peptide receptor radionuclide therapy (PRRT) in high grade neuroendocrine neoplasms: a systematic review and meta-analysis},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {6},
  pages = {3799--3808},
  doi = {10.1007/s00259-025-07726-w}
}
Kostenlos starten →